BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. 2004

R S Autar, and J Ananworanich, and W Apateerapong, and J Sankote, and A Hill, and B Hirschel, and D Cooper, and J Lange, and P Phanuphak, and K Ruxrungtham, and D Burger
The HIV Netherlands Australia Thailand Research Collaboration, The Thai Red Cross AIDS Research Center, Bangkok, Thailand. saskia@hivnat.com

OBJECTIVE A pharmacokinetic comparison of three dosing regimens of saquinavir/ritonavir was carried out: 1600/100 mg once-daily with 1000/100 mg twice-daily, and 1600/100 mg once-daily with 2000/100 mg once-daily. METHODS Twenty patients on saquinavir hard gel caps/ritonavir 1600/100 mg once-daily in combination with two nucleoside reverse transcriptase inhibitors for at least 4 weeks were enrolled and randomized to either saquinavir hard gel caps/ritonavir 1000/100 mg twice-daily or 2000/100 mg once-daily. Two pharmacokinetic curves were plotted, at baseline (day 0) and 7 days after the switch. Plasma concentrations were measured at 0, 2, 4, 6, 8, 10, 12 (and 24 for once-daily dosing) hours after drug intake by validated high-performance liquid chromatographic assay (HPLC). The area under the plasma concentration-time curve (AUC0-24 or AUC0-12), maximum and minimum concentration (Cmax and Cmin) and elimination half-life were calculated using a non-compartmental model. RESULTS Compared with saquinavir/ritonavir 1600/100 mg once-daily dosing, the saquinavir AUC and Cmin improved significantly when dosed as 1000/100 mg twice-daily (53% and 299%, respectively), and as 2000/100 mg once-daily (71% and 65%, respectively). Low Cmin in three subjects at baseline was corrected after switch to the other dosages. Saquinavir/ritonavir 2000/100 mg once-daily was also associated with a significant increase in saquinavir Cmax (52%) compared with saquinavir/ritonavir 1600/100 mg once-daily. CONCLUSIONS Saquinavir/ritonavir when dosed as 2000/100 mg once-daily or 1000/100 mg twice-daily achieves higher saquinavir plasma levels compared with saquinavir/ritonavir 1600/100 mg once-daily. Taking the convenience of once-daily dosing into consideration, dosage of 2000/100 mg once-daily may be preferred.

UI MeSH Term Description Entries
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D002214 Capsules Hard or soft soluble containers used for the oral administration of medicine. Capsule,Microcapsule,Microcapsules
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D005782 Gels Colloids with a solid continuous phase and liquid as the dispersed phase; gels may be unstable when, due to temperature or other cause, the solid phase liquefies; the resulting colloid is called a sol.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

R S Autar, and J Ananworanich, and W Apateerapong, and J Sankote, and A Hill, and B Hirschel, and D Cooper, and J Lange, and P Phanuphak, and K Ruxrungtham, and D Burger
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily.
April 2005, The Journal of antimicrobial chemotherapy,
R S Autar, and J Ananworanich, and W Apateerapong, and J Sankote, and A Hill, and B Hirschel, and D Cooper, and J Lange, and P Phanuphak, and K Ruxrungtham, and D Burger
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
January 2005, British journal of clinical pharmacology,
R S Autar, and J Ananworanich, and W Apateerapong, and J Sankote, and A Hill, and B Hirschel, and D Cooper, and J Lange, and P Phanuphak, and K Ruxrungtham, and D Burger
Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg.
December 2004, Antiviral therapy,
R S Autar, and J Ananworanich, and W Apateerapong, and J Sankote, and A Hill, and B Hirschel, and D Cooper, and J Lange, and P Phanuphak, and K Ruxrungtham, and D Burger
Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
August 2013, Therapeutic drug monitoring,
R S Autar, and J Ananworanich, and W Apateerapong, and J Sankote, and A Hill, and B Hirschel, and D Cooper, and J Lange, and P Phanuphak, and K Ruxrungtham, and D Burger
Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women.
December 2011, Therapeutic drug monitoring,
R S Autar, and J Ananworanich, and W Apateerapong, and J Sankote, and A Hill, and B Hirschel, and D Cooper, and J Lange, and P Phanuphak, and K Ruxrungtham, and D Burger
The use of saquinavir/ritonavir 1000/100 mg twice daily in patients with tuberculosis receiving rifampin.
December 2004, Antiviral therapy,
R S Autar, and J Ananworanich, and W Apateerapong, and J Sankote, and A Hill, and B Hirschel, and D Cooper, and J Lange, and P Phanuphak, and K Ruxrungtham, and D Burger
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
November 2006, The Journal of antimicrobial chemotherapy,
R S Autar, and J Ananworanich, and W Apateerapong, and J Sankote, and A Hill, and B Hirschel, and D Cooper, and J Lange, and P Phanuphak, and K Ruxrungtham, and D Burger
Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
April 2004, Antiviral therapy,
R S Autar, and J Ananworanich, and W Apateerapong, and J Sankote, and A Hill, and B Hirschel, and D Cooper, and J Lange, and P Phanuphak, and K Ruxrungtham, and D Burger
Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.
April 2002, Journal of acquired immune deficiency syndromes (1999),
R S Autar, and J Ananworanich, and W Apateerapong, and J Sankote, and A Hill, and B Hirschel, and D Cooper, and J Lange, and P Phanuphak, and K Ruxrungtham, and D Burger
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.
June 2004, Antiviral therapy,
Copied contents to your clipboard!